ARVN Historical PE Ratio Notes

— Arvinas (ARVN) is a clinical-stage biopharmaceutical company pioneering the development of targeted protein degradation therapies, primarily focused on oncology & neurodegenerative diseases. Unlike traditional small-molecule drugs that often inhibit the function of disease-causing proteins, Arvinas’ PROTAC�ae technology platform is designed to eliminate these proteins entirely from cells. This innovative, high-risk/high-reward approach means that Arvinas has historically generated little or no revenue, and its earnings per share (EPS) have often been negative as the company invests heavily in research & development. As a result, you'll notice that the historical PE (Price-to-Earnings) ratio for ARVN may be either extremely high, undefined, or not meaningful (since the “E” in PE is negative or minimal). This reflects the stock market's valuation of Arvinas as a growth story with potential for substantial future earnings, rather than one currently generating consistent profits. When reviewing historical charts & tables for price, earnings, and PE ratio, it's important to interpret these numbers within the context of the company's development pipeline, clinical milestones, & the speculative nature of early-stage biotech investments.

On this page we presented the ARVN Historical PE Ratio information for Arvinas' stock. The average ARVN historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 9.3. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ARVN historical PE based on this TTM earnings result method is 90.0. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ARVN historical PE result, against the recent PE: when this page was posted on 8/4/2026, the most recent closing price for ARVN had been 9.00, and the most recent quarterly earnings result, annualized, was 10.32. Meanwhile, the most recent TTM earnings summed to 0.1. From these numbers, we calculate the recent ARVN PE on 8/4/2026 based on annualized quarterly EPS was 0.9. Based on ARVN's history, that recent PE is low relative to the historical average, with the recent PE 90.3% lower than the historical average PE across our data set for Arvinas. Looking at the recent ARVN PE on 8/4/2026 based on TTM EPS, we calculate the ratio at 90.0.

For self directed investors doing their due diligence on ARVN or any other given stock, valuation analysis for ARVN can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Arvinas PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ARVN. Thanks for visiting, and the next time you need to research ARVN Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.